CONTINUUS Pharmaceuticals entered into a development contract with Roche to create an end-to-end Integrated Continuous Manufacturing (ICM) process for a new Roche antiviral medicine. The novel production process will be based on proprietary manufacturing technologies developed by CONTINUUS, and combines both Active Pharmaceutical Ingredient (API) production and Drug Product formulation into a single seamless line.
CONTINUUS will provide the technology platform and continuous manufacturing process development expertise, while Roche will oversee and guide the development process activities. This is the second collaboration between the two companies centering on continuous manufacturing; the previous engagement targeted specific CONTINUUS-proprietary unit operations, assessing their performance compared to batch technologies.
“We are very excited to continue our working relationship with Roche. This project is a key step in our vision to modernize the pharmaceutical manufacturing industry, as we progress to commercial implementation of our platform technology” said Salvatore Mascia, CEO of CONTINUUS Pharmaceuticals.